You are here: Industry Insights > Loxo Oncology

News List

Lilly and Foghorn enter partnership to develop new cancer medicines Pharmaceutical-Technology
December 15, 2021
Eli Lilly and Company’s research and development group Loxo Oncology at Lilly and Foghorn Therapeutics have entered a strategic partnership to develop new cancer therapies.
Lilly and Merus partner to develop T-Cell re-directing antibody therapies pharmaceutical-technology
January 21, 2021
Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.
Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195) worldpharmanews
February 18, 2019
Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology...
Lilly Announces Agreement to Acquire Loxo Oncology americanpharmaceuticalreview
January 08, 2019
Eli Lilly and Company and Loxo Oncology announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion ......
Blueprint’s Tagrisso combination shows early promise in NSCLC fiercebiotech
September 28, 2018
Based on these data, Blueprint is looking into testing the combination in more patients with the same treatment-resistant EGFR-mutant cancer.
Deals this week: Carma Therapeutics, Vectorite Biomedica, Loxo Oncology pharmaceutical-technology
June 19, 2017
Cellular immunotherapies developer Carma Therapeutics has completed a venture financing round co-led by AbbVie Biotech Ventures and HealthCap in order to raise funds required to advance the development of its adoptive cellular immunotherapy named CARMA-05